Loading company
ANI Pharmaceuticals Inc.
ANIP · Nasdaq · ·
Next earnings: November 6, 2026
$72.57-3.0%Sep 29 close
- 1M
- -0.4%
- 6M
- -1.5%
- 1Y
- -20.8%
- 5Y
- +127.8%
ANIP · Nasdaq · ·
Next earnings: November 6, 2026
$72.57-3.0%Sep 29 close
ANI Pharmaceuticals Inc. is scheduled to report next on November 6, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $266M | $211.4M | +25.87% |
| Profit | $24.7M | $8.5M | +189.05% |
| Profit per share | $1.05 | $0.36 | +191.67% |
| Free Cash Flow | $53.6M | $71.8M | -25.33% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from ANI Pharmaceuticals Inc.’s Item 2.02 8-K filed August 7, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
ANI Pharmaceuticals Inc. has no earnings call transcript available.